Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) \<50,000 copies/mL~* Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before enrollment with no intention of changing therapy for 3 months after randomization~* Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of study vaccine.~Exclusion Criteria:~* History of opportunistic infections within 12 months before the first study vaccination~* History of non-infectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy~* History of invasive pneumococcal disease~* Known hypersensitivity to any vaccine component~* Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease~* Coagulation disorder contraindicating intramuscular vaccination~* History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* Female participant: positive urine or serum pregnancy test~* Prior administration of any pneumococcal vaccine~* Received systemic corticosteroids for ≥14 consecutive days and have not completed within 30 days of enrollment~* Received immunosuppressive therapy~* Received a blood transfusion or blood products within 6 months of enrollment~* Participated in another clinical study of an investigational product within 2 months of enrollment~* Current user of recreational or illicit drugs or recent history of drug or alcohol abuse or dependence.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).